ライフサイエンスコーパス: complete therapy

1 etected in 9 of 21 patients (and 9 of 19 who completed therapy).

2 diac events were higher in those who did not complete therapy.

3 ent and increase the number of patients that complete therapy.

4 patients who initiated adjuvant trastuzumab completed therapy.

5 atment was well tolerated: 13 subjects (93%) completed therapy.

6 ntive therapy, 84 (20%) we intended to treat completed therapy.

7 (84%) of the remaining 49 detained patients completed therapy.

8 Among another 105 enrolled on DOPT, 63 (60%) completed therapy.

9 ted and two previously treated patients have completed therapy.

10 Thirty-two of 34 enrolled participants completed therapy.

11 post-therapy, 77.6% did so within 4 weeks of completing therapy.

12 side effects that prevent some patients from completing therapy.

13 had at least 2 RT-PCR assays performed after completing therapy.

14 ed intravascular coagulation and died before completing therapy.

15 patients remain alive up to 29 months after completing therapy.

16 hemotherapy or recurrence within 6 months of completing therapy.

17 ors of neurocognitive outcomes 2 years after completing therapy.

18 , and pyrazinamide concentrations: 110 (77%) completed therapy, 24 (17%) failed therapy, and 9 (6%) d

19 were discharged to an outpatient setting to complete therapy, 40 (24.1%) required inpatient care to

20 At follow-up, 131 patients completed therapy-64 taking spironolactone and 67 placeb

21 the recommended treatment period, those who completed therapy (66%) had a lower subsequent mortality

22 examined factors associated with failure to complete therapy and followed patients for active TB.

23 Of the 17 patients, 13 (76%) successfully completed therapy and 4 (24%) eventually underwent SOT.

24 All patients completed therapy and received the prescribed tumor apex

25 erapy and the response duration in those who completed therapy and responded.

26 easured as the response rate in patients who completed therapy and the response duration in those who

27 HIV-seropositive patients were enrolled: 61 completed therapy and were assessed for relapse.

28 erapy, 40 (24.1%) required inpatient care to complete therapy, and 3 died (1 from TB) before discharg

29 rrow, performed at least 1 month apart after completing therapy, are strongly associated with long-te

30 ntary admissions decreased and most patients completed therapy as outpatients.

31 All 70 patients enrolled completed therapy as planned and median follow-up was 17

32 ed isoniazid therapy after release, 15 (29%) completed therapy (chi-square = 13.50, p = 0.0002).

33 s was negative by PCR; this patient had just completed therapy for P. carinii pneumonia.

34 Over a 2-year period, 166 patients who had completed therapy for stage II (80.1%) or III (19.9%) br

35 on was largely age appropriate 2 years after completing therapy; however, the overall group demonstra

36 ecialized medical management for patients to complete therapy in a safe and supportive environment.

37 ed from 27.3% to 59.1% and approximately 70% completed therapy in 12 months.

38 nly for the subgroup of patients who did not complete therapy, in favor of later treatment (P < .001)

39 After completing therapy, mice underwent 5 monthly oral peanut

40 ates (undetectable viral load 12 weeks after completing therapy) of >90% in most patients.

41 Of the patients who completed therapy, only 17 were detained until treatment

42 as used as adjuvant therapy, if they did not complete therapy, or if they were still actively receivi

43 ase Activity Score in those patients who had completed therapy (P=0.002).

44 imens are unusual, and most infections after completing therapy resulted from new strains in patients

45 candidates or recipients were less likely to complete therapy than nonliver transplant patients (OR,

46 After 34 patients had completed therapy, the trial's Data Monitoring Committee

47 Thirteen patients were enrolled and 12 completed therapy, three at dose levels 1 and 2 and six

48 Eighteen patients completed therapy: three at 500 mg, six at 1,000 mg, thr

49 Sixty-four patients have completed therapy to date.

50 ren for whom antibiotic therapy records were complete, therapy was either started or changed for 88 (

51 ord with at least 5 years of follow-up after completing therapy were identified from our database.

52 on lost to follow-up and half the proportion completing therapy within 12 months.